NCT04303286

Brief Summary

The purpose of this study was to explore the correlation between postoperative recovery of liver function and gut microbiota in patients with hepatocellular carcinoma (HCC). Liver resection patients were divided into the recovery group and the recovery delay group according to the recovery level of liver function on the fifth day after the operation. Benign liver disease was used as a control. Statistical analysis was performed to compare the differences in gut microbiota between the three groups. Then, fecal microbiota transplantation was performed in a mouse hepatectomy model. Through this study, the investigators hope to understand the relationship between gut microbiota and postoperative recovery of liver function in patients with hepatocellular carcinoma, so as to provide a new therapeutic direction for patients in the aspect of perioperative liver function recovery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2018

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

March 5, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 11, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

May 12, 2022

Status Verified

May 1, 2022

Enrollment Period

2.2 years

First QC Date

March 5, 2020

Last Update Submit

May 11, 2022

Conditions

Outcome Measures

Primary Outcomes (6)

  • Diversity analysis

    We will use 16S rRNA sequencing to measure fecal sample. The alpha and beta diversity of gut microbiota between the groups will be analyzed, including a series of statistical analysis indexes such as Chao, Shannon, Simpsonace, Simpson and Coverage, in order to reflect the microbial community diversity.

    Before the surgery

  • Diversity analysis

    We will use 16S rRNA sequencing to measure fecal sample. The alpha and beta diversity of gut microbiota between the groups will be analyzed, including a series of statistical analysis indexes such as Chao, Shannon, Simpsonace, Simpson and Coverage, in order to reflect the microbial community diversity.

    Five days after the surgery

  • Species composition analysis

    We will use 16S rRNA sequencing to measure fecal sample. Based on the results of species annotation, the community histogram, the community heatmap and the Wayne map will be used to analyze the species composition of the sample, in order to explore the relationship between the species and the sample, and analyze the key microflora in the sample.

    Before the surgery

  • Species composition analysis

    We will use 16S rRNA sequencing to measure fecal sample. Based on the results of species annotation, the community histogram, the community heatmap and the Wayne map will be used to analyze the species composition of the sample, in order to explore the relationship between the species and the sample, and analyze the key microflora in the sample.

    Five days after the surgery

  • Species differential analysis

    We will use 16S rRNA sequencing to measure fecal sample. Based on the results of species annotation, the PCA、PCoA and NMDS analysis will be used to assess the similarities and differences in species composition between groups. To further screen the species with significant differences, the LEfSe difference discriminant analysis will be used.

    Before the surgery

  • Species differential analysis

    We will use 16S rRNA sequencing to measure fecal sample. Based on the results of species annotation, the PCA、PCoA and NMDS analysis will be used to assess the similarities and differences in species composition between groups. To further screen the species with significant differences, the LEfSe difference discriminant analysis will be used.

    Five days after the surgery

Study Arms (3)

Recovery Group

The liver function of HCC patients on the fifth day after the operation is recovered.

Recovery Delay Group

The liver function of HCC patients on the fifth day after the operation is delayed recovered.

Control Group

The patients on benign disease of the liver

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The cohort are the patients from the hepatic surgery of Tongji hospital.

You may qualify if:

  • The patient is diagnosed with liver cancer by b-mode ultrasonography before the surgery.
  • There is no antibiotic treatment, no severe diarrhea and regular diet within two weeks before the surgery.
  • It perform laparoscopic or open hepatectomy.
  • The postoperative pathological diagnosis is hepatocellular carcinoma.

You may not qualify if:

  • No hepatectomy is performed during the operation.
  • The patient is't hepatocellular carcinoma due to the postoperative pathological diagnosis.
  • No stool samples are collected during the perioperative period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The hepatic surgery of Tongji hospital

Wuhan, Hubei, 430030, China

Location

Related Publications (1)

  • Yu J, Zhu P, Shi L, Gao N, Li Y, Shu C, Xu Y, Yu Y, He J, Guo D, Zhang X, Wang X, Shao S, Dong W, Wang Y, Zhang W, Zhang W, Chen WH, Chen X, Liu Z, Yang X, Zhang B. Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma. Cell Host Microbe. 2024 Jan 10;32(1):131-144.e6. doi: 10.1016/j.chom.2023.11.011. Epub 2023 Dec 12.

Biospecimen

Retention: SAMPLES WITH DNA

feces, whole blood

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

  • Bixiang Zhang

    Tongji Hospital

    STUDY CHAIR
  • Jingjing Yu

    Tongji Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chairman of Department of General Surgery

Study Record Dates

First Submitted

March 5, 2020

First Posted

March 11, 2020

Study Start

October 1, 2018

Primary Completion

November 30, 2020

Study Completion

December 31, 2020

Last Updated

May 12, 2022

Record last verified: 2022-05

Locations